Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Breast Neoplasms 2Scleroderma, Localized 1Radiation Injuries 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Pneumonia 1Neurodermatitis 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lichen Planus 1Leukemia 1Keratoacanthoma 1Keloid 1Hemangioma 1Granuloma Annulare 1Dermoid Cyst 1Dendritic Cell Sarcoma, Interdigitating 1Cicatrix, Hypertrophic 1Cancer Pain 1Bone Neoplasms 1Asthma 1Arthritis, Rheumatoid 1Alopecia Areata 1

Interventions

Cyclophosphamide 56fludarabine phosphate 30Filgrastim 28Peripheral Blood Stem Cell Transplantation 27Radiotherapy 26Cyclosporine 23Busulfan 23Etoposide 21Mycophenolic Acid 20Whole-Body Irradiation 19Antilymphocyte Serum 19Methotrexate 17Methylprednisolone 15Melphalan 14Cytarabine 13Vincristine 11Tacrolimus 11Thiotepa 10Prednisone 10Cord Blood Stem Cell Transplantation 10Rituximab 9Doxorubicin 9Leucovorin 7aldesleukin 6Granulocyte Colony-Stimulating Factor 6sargramostim 5Psychiatric Rehabilitation 5Carboplatin 5Therapeutics 4Daunorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Dendritic Cell Sarcoma, Interdigitating × Adrenal Cortex Hormones × Clear all
NCT03003520 2023-05-22

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Celgene

Phase 2 Completed
46 enrolled 20 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡